Using 68 Ga-DOTATATE PET for Postoperative Radiosurgery and Radiotherapy Planning in Patients With Meningioma: A Case Series.
Journal
Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
received:
07
06
2022
accepted:
02
12
2022
medline:
19
6
2023
pubmed:
2
2
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
For patients with either an incompletely resected meningioma or recurrence after surgery, stereotactic radiosurgery is frequently used. MRI is typically used for stereotactic radiosurgery targeting, but differentiating tumor growth from postoperative change can be challenging. 68 Ga-DOTATATE, a positron emission tomography (PET) radiotracer targeting the somatostatin receptor type 2, has been shown to be a reliable meningioma biomarker. To evaluate the impact of 68 Ga-DOTATATE on treatment planning in patients who had previously undergone meningioma resection. We present a consecutive case series of 12 patients with pathology-proven meningioma who received a 68 Ga-DOTATATE PET between April 2019 and April 2021. Treatment planning was performed first using MRI. DOTATATE-PET images were then used to assess accurate tumor identification. Ten patients had WHO Grade 2 meningioma, and 2 patients had Grade 1 tumor. Eight patients had recurrent meningiomas, and 4 patients had newly diagnosed disease. Overall, 68 Ga-DOTATATE PET scans altered previously formulated treatment plans in 5 of 12 patients. In addition, 9 of 12 patients had disease foci not appreciated on MRI. In this series, incorporating 68 Ga-DOTATATE PET imaging had clinical utility for most patients in whom it was used. It proved particularly adept in demonstrating intraosseous meningiomas, differentiating recurrence from postoperative changes, and identifying subcentimeter disease foci. It is an imaging modality that our center will continue to use as a means of improving postoperative treatment plans after the surgical resection of meningiomas.
Sections du résumé
BACKGROUND
For patients with either an incompletely resected meningioma or recurrence after surgery, stereotactic radiosurgery is frequently used. MRI is typically used for stereotactic radiosurgery targeting, but differentiating tumor growth from postoperative change can be challenging. 68 Ga-DOTATATE, a positron emission tomography (PET) radiotracer targeting the somatostatin receptor type 2, has been shown to be a reliable meningioma biomarker.
OBJECTIVE
To evaluate the impact of 68 Ga-DOTATATE on treatment planning in patients who had previously undergone meningioma resection.
METHODS
We present a consecutive case series of 12 patients with pathology-proven meningioma who received a 68 Ga-DOTATATE PET between April 2019 and April 2021. Treatment planning was performed first using MRI. DOTATATE-PET images were then used to assess accurate tumor identification.
RESULTS
Ten patients had WHO Grade 2 meningioma, and 2 patients had Grade 1 tumor. Eight patients had recurrent meningiomas, and 4 patients had newly diagnosed disease. Overall, 68 Ga-DOTATATE PET scans altered previously formulated treatment plans in 5 of 12 patients. In addition, 9 of 12 patients had disease foci not appreciated on MRI.
CONCLUSION
In this series, incorporating 68 Ga-DOTATATE PET imaging had clinical utility for most patients in whom it was used. It proved particularly adept in demonstrating intraosseous meningiomas, differentiating recurrence from postoperative changes, and identifying subcentimeter disease foci. It is an imaging modality that our center will continue to use as a means of improving postoperative treatment plans after the surgical resection of meningiomas.
Identifiants
pubmed: 36722951
doi: 10.1227/neu.0000000000002377
pii: 00006123-202307000-00011
doi:
Substances chimiques
copper dotatate CU-64
0
Gallium-68
98B30EPP5S
Organometallic Compounds
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
95-101Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © Congress of Neurological Surgeons 2023. All rights reserved.
Références
Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1821-1834.
Galldiks N, Albert NL, Sommerauer M, et al. PET imaging in patients with meningioma—report of the RANO/PET Group. Neuro Oncol. 2017;19(12):1576-1587.
Ivanidze J, Roytman M, Lin E, et al. Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas. J Neuroimaging. 2019;29(5):650-656.
Kunz WG, Jungblut LM, Kazmierczak PM, et al. Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET/CT compared with contrast-enhanced MRI. J Nucl Med. 2017;58(10):1580-1587.
Galldiks N, Lohmann P, Albert NL, Tonn JC, Langen KJ. Current status of PET imaging in neuro-oncology. Neurooncol Adv. 2019;1(1):1-11.
Dutour A, Kumar U, Panetta R, et al. Expression of somatostatin receptor subtypes in human brain tumors. J Cancer. 1998;76(5):620-627.
Salgues B, Graillon T, Guedj E. Image of the month [68 Ga]Ga-DOTA-TOC PET/CT fused to MRI in post-operative evaluation of olfactory groove meningioma: a case on millimetric remnants. Eur J Nucl Med Mol Imaging. 2021;48(1):316-317.
Vay SU, Werner JM, Kabbasch C, et al. Uncovering an optic nerve sheath meningioma using 68Ga-DOTATATE PET/CT. Clin Nucl Med. 2021;46(9):e464-e465.
Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. J Med Case Rep. 2013;7(1):223.
Henze M, Schuhmacher J, Hipp P, et al. PET imaging of somatostatin receptors using [68GA]DOTA-d-Phe1-Tyr3-Octreotide: first results in patients with meningiomas. J Nucl Med. 2001;42(7):1053-1056.
Einhellig HC, Siebert E, Bauknecht HC, et al. Comparison of diagnostic value of 68 Ga-DOTATOC PET/MRI and standalone MRI for the detection of intracranial meningiomas. Sci Rep. 2021;11(11):1-9.
Jenkinson MD, Javadpour M, Haylock BJ, et al. The ROAM/EORTC-1308 trial: radiation versus observation following surgical resection of atypical meningioma: study protocol for a randomised controlled trial. Trials. 2015;16(1):1-8.
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery—Full Text View—ClinicalTrials.gov. Accessed February 6, 2022. https://clinicaltrials.gov/ct2/show/NCT03180268 .
Ma D, Rana Z, Viswanatha S, et al. RADT-39. 68Ga- DOTATATE CT/PET for gamma knife radiosurgery planning and target delineation in patients with meningioma. Neuro Oncol. 2020;22(suppl 2):ii190.
Gwak HS, Youn SM, Chang U, et al. Usefulness of 18F-fluorodeoxyglucose PET for radiosurgery planning and response monitoring in patients with recurrent spinal metastasis. Minim Invasive Neurosurg. 2006;49(3):127-134.
Bagrosky BM, Hayes KL, Koo PJ, Fenton LZ. 18F-FDG PET/CT evaluation of children and young adults with suspected spinal fusion hardware infection. Pediatr Radiol. 2013;43(8):991-1000.
Follenfant E, Balamoutoff N, Lawson-Ayayi S, et al. Added value of [18 F] fluorodeoxyglucose positron emission tomography/computed tomography for the diagnosis of post-operative instrumented spine infection. Joint Bone Spine. 2019;86(4):503-508.
Seifen T, Rodrigues M, Rettenbacher L, et al. The value of (18)F-fluoride PET/CT in the assessment of screw loosening in patients after intervertebral fusion stabilization. Eur J Nucl Med Mol Imaging. 2015;42(2):272-277.
Rager O, Schaller K, Payer M, Tchernin D, Ratib O, Tessitore E. SPECT/CT in differentiation of pseudarthrosis from other causes of back pain in lumbar spinal fusion: report on 10 consecutive cases. Clin Nucl Med. 2012;37(4):339-343.
Pouldar D, Bakshian S, Matthews R, Rao V, Manzano M, Dardashti S. Utility of 18F sodium fluoride PET/CT imaging in the evaluation of postoperative pain following surgical spine fusion. Musculoskelet Surg. 2017;101(2):159-166.
Vorster M, Maes A, van Dewiele C, Sathekge M. Gallium-68: a systematic review of its nononcological applications. Nucl Med Commun. 2013;34(9):834-854.
Zampetti B, Attanasio R, Boniardi M, Cozzi R. False positive of 68Ga-DOTATATE PET-CT in a paraganglioma. Endocr Metab Immune Disord Drug Targets. 2020;21(7):1352-1355.
Lococo F, Cafarotti S, Filice A, Bertagna F, Treglia G. A false positive finding on the PET of somatostatin receptor due to a chondromyxoid fibroma. Rev Esp Med Nucl Imagen Mol. 2014;33(4):245-246.